Methotrexate and Hyponatremia
Methotrexate can cause hyponatremia, though this is not a commonly emphasized toxicity in standard prescribing guidelines, and when it occurs, it should be managed by discontinuing the drug and treating the hyponatremia according to standard protocols based on symptom severity and volume status.
Does Methotrexate Cause Hyponatremia?
Yes, methotrexate is associated with hyponatremia, though this adverse effect receives limited attention in major prescribing guidelines. The evidence shows:
- Intrathecal methotrexate has documented cases of recurrent hyponatremia that appears to be mediated by a natriuretic peptide mechanism rather than inappropriate ADH secretion 1
- Methotrexate is listed among anticancer drugs associated with hyponatremia 2
- The mechanism may involve syndrome of inappropriate antidiuresis (SIAD), though the exact pathway is not fully characterized 3
Important caveat: The British Association of Dermatologists guidelines 4 and FDA labeling 5 extensively detail methotrexate's renal, hepatic, hematologic, and pulmonary toxicities but do not specifically mention hyponatremia as a primary concern. This suggests hyponatremia is a rare or underrecognized adverse effect compared to the drug's major toxicities.
Clinical Recognition
Monitor for hyponatremia in patients on methotrexate who develop:
- Nonspecific symptoms: nausea, confusion, weakness, headache
- More severe manifestations: seizures, altered mental status, coma (if severe hyponatremia develops)
- Gastrointestinal symptoms (vomiting, diarrhea) that could compound electrolyte abnormalities 5
Key monitoring point: Since methotrexate commonly causes nausea (up to 25% of patients) 4 and gastrointestinal toxicity requiring drug discontinuation 5, these symptoms may mask or overlap with hyponatremia symptoms.
Management Algorithm
1. Immediate Assessment
- Check serum sodium level
- Assess symptom severity and rapidity of onset
- Determine volume status (hypovolemic, euvolemic, or hypervolemic) 6
- Review concurrent medications that may contribute (diuretics, antidepressants, other drugs causing SIAD) 7
2. Discontinue Methotrexate
- Stop methotrexate immediately if hyponatremia is confirmed
- Given methotrexate's renal excretion and potential for accumulation 4, 5, discontinuation is critical to prevent worsening
3. Treat Based on Severity
Severely symptomatic hyponatremia (seizures, coma, somnolence, cardiorespiratory distress):
- Medical emergency requiring hypertonic saline (3% NaCl)
- Give 100-150 mL IV bolus to increase serum sodium by 4-6 mEq/L within 1-2 hours 6, 8
- Do not exceed 10 mEq/L correction in first 24 hours to avoid osmotic demyelination syndrome 6, 9
- Frequent sodium monitoring (every 2-4 hours initially)
Asymptomatic or mild hyponatremia:
- Adequate solute intake (salt and protein)
- Initial fluid restriction of 500 mL/day, adjusted based on sodium levels 8
- If SIAD is confirmed and fluid restriction fails, consider urea or vaptans as second-line 8
4. Monitor for Overcorrection
- Have hypotonic fluids or desmopressin ready if correction is too rapid 8
- Osmotic demyelination can cause irreversible neurological damage (parkinsonism, quadriparesis, death) 6
Special Considerations
Renal function: Methotrexate is renally excreted and can cause renal damage 5. Impaired renal function increases methotrexate toxicity risk and may complicate hyponatremia management. Check eGFR and adjust approach accordingly 4.
Third-space accumulations: Methotrexate exits slowly from pleural effusions or ascites, prolonging half-life and increasing toxicity 5. Evacuate fluid before resuming treatment if methotrexate is to be restarted.
Do not restart methotrexate until hyponatremia is fully corrected and the risk-benefit has been carefully reconsidered, as recurrent hyponatremia has been documented with repeated methotrexate exposure 1.